Faslodex (fulvestrant) works by binding to estrogen receptors on breast cancer cells and triggering their destruction, cutting off the signal that fuels tumor growth. Unlike older hormone therapies that simply block the receptor, Faslodex eliminates it entirely, earning it the classification of a selective estrogen receptor degrader, or SERD. This makes it a distinct and important tool in treating hormone receptor-positive breast cancer.
How Faslodex Destroys Estrogen Receptors
Hormone receptor-positive breast cancer cells rely on estrogen to grow. Estrogen binds to a protein called the estrogen receptor (ER) inside these cells, which then switches on genes that tell the cell to divide. Faslodex works by latching onto this same receptor, but instead of activating it, the drug changes its shape in a way that marks it for disposal.
Once Faslodex binds the receptor, it triggers a chain of events inside the cell. The receptor becomes trapped against the cell’s internal scaffolding, a structural network called the nuclear matrix. There, the cell’s built-in recycling system, the ubiquitin-proteasome pathway, breaks the receptor down into pieces. Research published in the Journal of Biological Chemistry showed that this process depends on specific structural proteins (cytokeratin 8 and 18) inside the cancer cell. In breast cancer cells that lack these proteins, Faslodex-induced receptor degradation does not occur, which helps explain why the drug’s effectiveness can vary between tumor types.
The result is straightforward: with fewer estrogen receptors available, the cancer cell loses its ability to receive estrogen’s growth signal. No receptor, no signal, no fuel for growth.
How It Differs From Tamoxifen
If you’ve heard of tamoxifen or similar drugs, you might wonder why Faslodex exists at all. The difference comes down to what happens after the drug binds the estrogen receptor.
Tamoxifen belongs to a class called selective estrogen receptor modulators (SERMs). These drugs sit in the receptor and block estrogen from binding, but they don’t destroy the receptor itself. More importantly, SERMs can act like a partial estrogen mimic in some tissues. Tamoxifen blocks estrogen in the breast but can stimulate estrogen-like activity in the uterus and bones. This dual nature is useful in some contexts but creates limitations and side effects in others.
Faslodex has no such dual action. Because it forces the receptor to be physically degraded, there is no receptor left to produce any estrogen-like signaling in any tissue. This pure anti-estrogen profile means the drug leaves no residual activity that cancer cells could exploit, which is particularly valuable when cancer has progressed on a SERM like tamoxifen.
What Faslodex Is Used For
Faslodex is approved for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is used both as a standalone treatment and in combination with other targeted therapies. In practice, it is most often prescribed for women whose cancer has progressed after prior hormone therapy, though it can also be used as a first-line treatment in the advanced setting.
One of the most significant developments in recent years is pairing Faslodex with a class of drugs called CDK4/6 inhibitors. A meta-analysis of randomized clinical trials found that adding one of these inhibitors to Faslodex reduced the risk of cancer progression by 47% compared to Faslodex alone. Overall survival also improved significantly, with a 23% reduction in the risk of death for patients on the combination. This combination has become a standard approach for many patients with advanced hormone receptor-positive breast cancer.
How It’s Given
Faslodex is not a pill. It is given as an intramuscular injection, 500 mg total, split into two separate injections (one in each buttock). Each injection takes one to two minutes to administer. The initial loading schedule is designed to get drug levels up quickly: injections on day 1, day 15, and day 29, then once monthly after that.
The drug has an unusually long half-life of about 40 days, which is why monthly dosing works. Steady-state levels in the blood build up gradually over the first three to six doses, meaning the full therapeutic effect may take a few months to establish. This slow accumulation is normal and expected.
Common Side Effects
Clinical trials of the 500 mg dose showed a relatively manageable side effect profile. The most frequently reported issues were injection site pain (about 12% of patients), nausea (around 10%), and bone pain (about 9%). These numbers come from the CONFIRM trial, which enrolled 361 patients at the standard dose.
Notably, the current 500 mg dose actually produces less nausea than the older 250 mg dose used in earlier studies, where 26% of patients reported nausea. The higher dose was ultimately chosen because it improved effectiveness without worsening the overall side effect burden. Most side effects are mild to moderate and manageable for the majority of patients receiving the drug long-term.